United States
BCMA (mouse):Fc (human), (recombinant)
| ALX-522-079-C050 | 50 µg | 329.00 USD |  |
||
Product Specification
| Alternative Name: | TNFRSF 17, B cell maturation protein, CD269 |
| Concentration: | 1mg/ml after reconstitution. |
| Endotoxin Content: | <0.1EU/µg purified protein (LAL test; Bio Whittaker). |
| MW: | ~35kDa (SDS-PAGE). |
| Purity: | ≥90% (SDS-PAGE) |
| Formulation: | Lyophilized. Contains PBS. |
| Biological Activity: | Blocks the binding of mouse BAFF and human APRIL to their receptors BCMA and TACI, inhibiting BAFF and APRIL-mediated splenocyte survival. |
| Source/Host: | Produced in HEK 293 cells. The extracellular domain of mouse BCMA (aa 1-46) is fused at the C-terminus to a linker peptide (2 aa) and the Fc portion of human IgG1. |
| Reconstitution: | Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein. |
| Specificity: | Binds mouse and human BAFF and human APRIL. |
| Application: | Flow Cytometry: Detection of membrane-bound mouse BAFF and human APRIL in combination with fluorescently labelled Ab to human IgG1. |
| Long Term Storage: | -20°C |
| Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
| Handling: | After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
| Background / Technical Information: | UniProt ID O88472: BCMA (mouse) AfCS Signaling Gateway ID A000374: BCMA (mouse) |
Inhibition of rhsBAFF-mediated splenocyte survival.
Figure: rmBCMA:Fc inhibits rhsBAFF-mediated activation of freshly isolated splenocytes. Concentration of rmBCMA:Fc (Prod. Nr. ALX-522-079) to achieve complete inhibition depends on the concentration of rhsBAFF (Prod. Nr. ALX-522-025) used. A ratio (rhsBAFF:rmBCMA:Fc) 1:50 and higher is recommended.
Method: On day 0 splenocytes were isolated from a freshly collected C57Bl6 spleen. An aliquot of the splenocytes was analyzed on FACS, and B cells were gated on the SSC-FSC panel. FACS settings were saved. The rest of the cells was put in culture with media alone, with the indicated concentration of rhsBAFF alone or in the presence of an excess of rmBCMA:Fc (50µg/ml). After three days in culture, cells were again analyzed on FACS with the saved setting. Splenocytes survival index (=ratio of %living/%dead cells) was calculated and plotted.
Figure: rmBCMA:Fc inhibits rhsBAFF-mediated activation of freshly isolated splenocytes. Concentration of rmBCMA:Fc (Prod. Nr. ALX-522-079) to achieve complete inhibition depends on the concentration of rhsBAFF (Prod. Nr. ALX-522-025) used. A ratio (rhsBAFF:rmBCMA:Fc) 1:50 and higher is recommended.
Method: On day 0 splenocytes were isolated from a freshly collected C57Bl6 spleen. An aliquot of the splenocytes was analyzed on FACS, and B cells were gated on the SSC-FSC panel. FACS settings were saved. The rest of the cells was put in culture with media alone, with the indicated concentration of rhsBAFF alone or in the presence of an excess of rmBCMA:Fc (50µg/ml). After three days in culture, cells were again analyzed on FACS with the saved setting. Splenocytes survival index (=ratio of %living/%dead cells) was calculated and plotted.
Please mouse over
Product Literature References
Product Toolbox
PRODUCT RESOURCES
Datasheet
RELATED PRODUCTS
By catalog section:
By biological activity:
BCMA Recombinant proteinPRODUCT SUPPORT
Technical ServiceBulk Quantity Quote
Customer Service
